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CTLA‑4 rs231775 and risk of acute 
renal graft rejection: an updated 
meta‑analysis with trial sequential 
analysis
Sarah Cargnin1, Ubaldina Galli2, Jae Il Shin3 & Salvatore Terrazzino1*
Contrasting results exist on the association between CTLA‑4 rs231775 and acute rejection in kidney 
transplant recipients. We herein conducted an updated systematic review with meta‑analysis 
and trial sequential analysis (TSA) to clarify this relationship and to establish whether the current 
evidence is sufficient to draw firm conclusions. In addition, noteworthiness of significant pooled odds 
ratios (ORs) was estimated by false positive report probability (FPRP). A comprehensive search was 
performed through PubMed, Web of Knowledge, Cochrane Library and Open Grey up to October 2019. 
Fifteen independent cohorts, including a total of 5,401 kidney transplant recipients, were identified 
through the systematic review. Overall, no association was detected with the allelic (OR 1.07, 95% CI 
0.88–1.30, P = 0.49), dominant (OR 0.94, 95% CI 0.73–1.22, P = 0.66) or the recessive (OR 1.18, 95% CI 
0.97–1.43, P = 0.096) model of CTLA‑4 rs231775. In each genetic model, the cumulative Z‑curve in TSA 
crossed the futility boundary and entered the futility area. In addition, none of the significant genetic 
comparisons detected in the subsequent and sensitivity analyses or in previously reported meta‑
analyses were found to be noteworthy by FPRP. In conclusion, this study provides strong evidence 
that CTLA‑4 rs231775 is not a clinically‑relevant genetic risk determinant of acute rejection after renal 
transplantation.
Cytotoxic T lymphocyte antigen-4 (CTLA-4, also known as CD152) is a transmembrane homodimer glycopro-
tein expressed by activated effector T cells (Teffs) that negatively regulates T cell-mediated immune  responses1. 
CTLA-4 exerts its immunosuppressive function through a variety of mechanisms which include competition 
with the co-stimulatory CD28 molecule for binding to their shared B7 ligands (CD80/CD86) on the antigen-
presenting cells (APC)2, and interference with TCR-mediated signal  transduction3. Given the key role of CTLA4 
on regulation of allograft rejection and  tolerance4,5, a great attention has been focused on the relationship between 
CTLA-4 genetic variation and graft outcome following solid organ  transplantation6–9.
The human CTLA-4 gene is located on the short arm of the second chromosome (2q33) and consists of four 
exons encoding respectively the leader sequence peptide, an extracellular immunoglobulin like domain contain-
ing the binding site, a transmembrane domain and a cytoplasmic  tail10,11. The single-nucleotide polymorphism 
(SNP) rs231775 of the CTLA-4 gene, also referred as + 49A>G, causes a threonine-to-alanine substitution at 
codon 17 in the peptide leader sequence, and guanine at this position is related to reduced CTLA-4 protein 
 expression12. Over the last fifteen years, several efforts have been made to evaluate the impact of CTLA-4 rs231775 
on the risk of acute rejection in kidney transplant recipients, however the results differed among studies, which 
reported a lack of  association13,14 or a higher risk of acute renal rejection among GG  carriers15,16 or inconclusive 
findings because of low sample  size17–19. The reasons for these conflicting and inconclusive results may be the 
different ethnicity, the clinical heterogeneity, the low statistical power or a combination of these factors.
Up to now, six meta-analyses have been conducted to clarify the role of CTLA-4 rs231775 on the risk of acute 
renal graft  rejection20–25. However, all these studies did not take into account the risk of random errors due to 
open
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sparse data and multiple meta-analytic up-dates26,27, which often result in false positive (type-1 error) and false 
negative (type-2 error) findings. Given that the above-mentioned issues can be addressed by application of trial 
sequential analysis (TSA) to meta-analytic  results28 and the recent publication of two novel primary  studies29,30, 
we herein conducted an updated meta-analysis with TSA to assess reliability of the accumulated evidence on 
the relationship between CTLA-4 rs231775 and acute renal transplant rejection. In addition, noteworthiness of 
significant pooled estimates from the present and previous meta-analyses was estimated by false positive report 
probability (FPRP).
Materials and methods
Literature search and selection criteria. This systematic review was conducted in accordance with the 
PRISMA Statement  principles31. A computerized literature search was carried out on PubMed, Web of Knowl-
edge, Cochrane Library and Open Grey (last search up October 17th, 2019) by using the Boolean combinations 
of the key terms: (cytotoxic T-lymphocyte antigen 4 OR CTLA4 OR CTLA-4 OR GWAS OR genome-wide 
association study) AND (polymorphism OR polymorphisms OR SNP OR SNPs OR genotype OR genotypes OR 
allele OR alleles OR variant OR variants) AND (kidney OR renal) AND rejection. Eligible studies were required 
to meet the following inclusion criteria: (i) investigating the association between CTLA-4 rs231775 and acute 
rejection (AR) in kidney transplant recipients (KTRs) (ii) reporting sufficient data for estimating an odds ratio 
(OR) with 95% confidence interval (CI) for the association with CTLA-4 rs231775. Exclusion criteria were: not 
human studies or not related to the research topics; case reports, editorials and meeting abstracts; narrative 
reviews, systematic reviews with or without meta-analysis; duplication of previous publications. The potentially 
relevant articles were then read in their entirety to assess their appropriateness for inclusion in the systematic 
review. Reference lists of retrieved studies were also checked to identify other potentially eligible studies. If 
two or more studies shared part of the same patients’ population, the one with the larger sample size or more 
complete data was included. The corresponding authors were contacted by e-mail when the eligible paper had 
insufficient information for calculation of OR and 95% CI. Studies were excluded if the corresponding author 
did not answer to the e-mail or was unable to provide the requested data.
Data extraction and study quality assessment. From each identified study the following data were 
extracted: name of first author, year of publication, study location, ethnicity, mean age, male/female ratio, donor 
type (i.e. living or deceased), immunosuppressive drugs, criteria for diagnosis of acute rejection, number of 
KTRs with and without AR, timing of AR after kidney transplantation, method of CTLA-4 rs231775 genotyp-
ing, and allele/genotype counts. Methodological study quality was assessed using the Newcastle–Ottawa scale 
(NOS) for cohort studies (available at: https ://www.ohri.ca/progr ams/clini cal-epide miolo gy/oxfor d-asp), which 
consists of three components: (I) selection and definition of the study groups (0–4 points); (II) comparability 
of the cohorts (0–2 points); and (III) ascertainment of outcomes (0–3 points). Studies with a NOS score ≥ 7 out 
of 9 were considered of higher quality. All studies were independently analyzed by two reviewers (S.T. and S.C.) 
and any discrepancies in study selection, data extraction and methodological quality evaluation were resolved 
through consensus.
Data synthesis and analysis. For each study, the Hardy–Weinberg Equilibrium (HWE) was calculated 
using the Pearson’s goodness-of-fit chi-square test implemented in the online Finetti’s program (available at 
https ://ihg.gsf.de/cgi-bin/hw/hwa1.pl). ORs were pooled based on the allelic (G vs. A), dominant (GG/AG vs. 
AA) or recessive (GG vs. AG/AA) genetic contrast of CTLA-4 rs231775 by using the random-effects (DerSimo-
nian–Laird method) model, which takes into account both within study variance and cross-study  variance32. In 
case of lack of heterogeneity, the random effects model coincides with the fixed-effect  model33. Between-study 
heterogeneity was tested using the Q statistic, with a p-value < 0.10 indicating the presence of significant het-
erogeneity among studies. Heterogeneity was also quantified by the  I2 metric, with  I2 values > 50% indicating 
high  heterogeneity34. The robustness of overall estimates was verified by conducting subgroup and sensitivity 
analyses. The presence of publication bias or a difference between small and large studies (’small-study effects’) 
in the overall analyses was evaluated graphically by drawing funnel plots and statistically by means of Egger’s 
 test35. In case of statistical evidence of funnel plot asymmetry (P-value of the Egger’s test < 0.10), the ‘trim-and-
fill’ method was used to adjust the overall pooled estimate for potential publication size or small study  effects36. 
All analyses were performed using ProMeta software (version 2; Internovi di Scarpellini, Daniele SAS, Cesena, 
Italy) and the significance of pooled ORs was set at P < 0.05. Noteworthiness of significant pooled ORs was also 
estimated by false positive report probability (FPRP)37, which is calculated based on the statistical power of the 
test, the observed P-value, and a given prior probability for the association. FPRP values were calculated at the 
prior probability of 0.001 (expected for a candidate gene)38 to detect ORs of 1.50 (or its reciprocal 1/1.5 = 0.67), 
by using the Excel spreadsheet provided by Wacholder et al.39. A significant result (P < 0.05) with an FPRP value 
of less than 0.2 indicated a noteworthy association.
Trial sequential analysis. Trial sequential analysis (TSA) allows to control the risk of type I (false posi-
tive) and type II (false negative) errors of conventional meta-analysis and to calculate the required information 
size (RIS), that is the required number of participants in a reliable and conclusive meta-analysis27. We estimated 
the RIS based on an overall 5% risk of a type I error (two sided α = 0.05), a statistical test power of 80% (β = 0.2) 
and an “a priori” relative risk difference (reduction or increase) of 15%. In addition, we set the event proportion 
in the reference genotype or allele group as the median value across studies included in the meta-analysis, and 
we adjusted the required information size for study heterogeneity by applying a  D2 adjustment  factor39. If the 
cumulative Z curve crosses the trial sequential monitoring boundaries with achievement of RIS, it means that a 
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sufficient level of evidence has been reached and further studies are unneeded. When the Z curve does not cross 
any of the boundaries and the RIS has not been reached, it can be concluded that more studies are required to 
reach a sufficient conclusion. If the cumulative Z curve crosses the futility boundaries, the conclusion of indis-
crimination between two groups is accepted under the given  conditions27,40. TSA was performed using Trial 
Sequential Analysis  software41 version 0.9.5.10 beta (available at www.ctu.dk/tsa).
Results
Literature screening process and characteristics of the identified studies. The flow chart 
illustrating the overall literature selection process is illustrated in Fig. 1. Briefly, the literature search on Pub-
Med, Web of Knowledge, Cochrane Library and Open Grey resulted in a total of 151 citations. After remov-
ing of 50 duplicated records, the remaining 101 studies were evaluated by carefully reading of titles, abstracts 
and full texts. After exclusion of additional 87 not relevant papers, 14 studies describing a total of 15 cohorts 
were included in the systematic review of association between CTLA-4 rs231775 and risk of acute renal graft 
 rejection13–19,29,30,42–46. The main characteristics of the identified studies are summarized in Table 1. In brief, stud-
ies were published between 2005 and 2019, mean age ranged from 30 to 49.6 years, and sample size varied from 
63 to 2,872. The most represented ethnic populations were Caucasian, Asian and African, which were included, 
respectively, in  eight13,14,18,19,30,42,44,46,  three15,16,45 and two  studies30,43. The largest  study30 included a cohort of 
European Americans (n = 2,390) and a cohort of African Americans (n = 482). In the majority of the identified 
studies, patients received renal allografts from living or cadaveric donors, while in 4 studies the transplanted 
kidney came exclusively from a cadaveric  donor13–15,18.
CTLA-4 rs231775 was found in Hardy–Weinberg equilibrium (HWE) in 9  studies14–19,30,43–45; it signifi-
cantly deviated from HWE in three  studies16,29,42, while it was not computable in two  studies13,46 which reported 
genotype data as a combined group (AG/AA vs. GG). The distribution of CTLA-4 rs231775 genotypes for 
each included cohort and timing of AR assessment after kidney transplantation is shown in Table 2. In seven 
 studies15–17,19,30,42,45 the association of CTLA-4 rs231775 with AR was assessed during the first year post-trans-
plant. Other study characteristics, including immunosuppressive drugs, criteria used for acute rejection diag-
nosis, and the genotyping method of CTLA-4 rs231775 are reported in Supplementary Material, Table S1. With 
regard to the study quality, the overall NOS scores ranged from 3 to 9 (median 7) (Table 1). Ten studies with a 
NOS score ≥ 7 were considered of higher  quality13–16,19,29,30,42,45,46. Individual scores for each item of NOS in the 
identified studies are shown in Supplementary Material, Table S2.
Quantitative data synthesis. A total of 15 cohorts including 5,401 KTRs were available for the meta-
analysis of CTLA-4 rs231775 under the recessive contrast model (GG vs. AG/AA), while 13 cohorts enrolling 
4,443 KTRs were available for the allelic (G vs. A) or the dominant (GG/AG vs. AA) model. A summary of 
random meta-analyses on the effect of CTLA-4 rs231775 on the risk of acute renal graft rejection is shown in 
Table 3. The pooled results showed no association with the allelic (G vs. A, OR 1.07, 95% CI 0.88–1.30, P = 0.49; 
Figure 1.  Flow chart of literature search and selection process of eligible studies.
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Table 1.  Characteristics of studies included in the meta-analysis of association between CTLA-4 rs231775 and 
acute renal allograft rejection. AA subgroup of African Americans; AR acute rejection group; EA subgroup of 
European Americans; HWE Hardy–Weinberg Equilibrium; KT kidney transplantion; NAR no acute rejection 
group; NOS Newcastle–Ottawa scale.




mean ± SD/range) Male/female
Donor type 
(living/deceased)






Dmitrienko42 2005 Canada (Caucasian) 100 (50/50) 44 ± 10.5 57/43 40/59  ≤ 1 year 0.04 8
Gendzekhadze17 2006 Venezuela (Latino) 63 (30/33) 40 ± 10 37/26 33/30  ≤ 3 months 0.51 6
Gorgi43 2006 Tunisia (African) 70 (31/39) 30 (12–56) 44/26 – – 0.18 3
Wiśniewski44 2006 Poland (Caucasian) 91 (38/53) – – –  ≥ 6 months 0.06 6
Haimila13 2009 Finland (Caucasian) 678 (109/535) 49.6 (17.8–74.5) 430/248 0/678 – NC 8
Kim45 2010 Korea (Asian) 325 (59/266) 40.1 ± 11.4 198/127 –  ≤ 6 months 0.56 8
Kusztal46 2010 Poland (Caucasian) 314 (102/212) 41.9 ± 12.1 184/130 2/312  ≥ 5 years NC 7
Domański14 2012 Poland (Caucasian) 269 (70/199) 47.6 ± 13.0 166/103 0/269  ≤ 5 years 0.30 7
Gao15 2012 China (Asian) 167 (45/122) 46.8 ± 11.3 105/62 0/167  ≤ 6 months 0.77 8
Canossi18 2013 Italy (Caucasian) 72 (37/35) – – 0/72  ≥ 6 months 0.67 4
Misra16 2014 India (Asian) 190 (36/154) – – –  ≤ 3 months 0.006 7
Ruhi19 2015 Turkey (Caucasian) 81 (34/47) 35.8 ± 11.7 62/19 81/0  ≤ 6 months 0.74 8
Niknam29 2017 Iran (Iranian) 172 (45/127) 38.3 ± 14.3 113/59 73/99  ≥ 3 months 0.02 7
Oetting30 2019
USA (European Americans) 2,390 (421/1969) 50.4 ± 14.7 1,500/890 1617/773  > 12 months 0.84EA
9
(African Americans) 482 (71/411) 46.9 ± 12.2 303/179 155/327  ≤ 12 months 0.35AA
Table 2.  Distribution of CTLA-4 rs231775 among the 15 identified cohorts. AR acute rejection group; KT 
kidney transplantation; M months; NAR no acute rejection group; Y year.
First  authorref
Year Ethnicity Time considered after KT
AR NAR
AA AG GG Total AA AG GG Total
Dmitrienko42
2005 Caucasian  ≤ 1 Y 18 29 3 50 23 24 3 50
Gendzekhadze17
2006 Latino  ≤ 3 M 9 16 5 30 17 11 5 33
Gorgi43
2006 African – 7 10 14 31 2 15 22 39
Wiśniewski44
2006 Caucasian  ≥ 6 M 13 13 12 38 19 23 11 53
Haimila13
2009 Caucasian – 37 – – 109 151 – – 535
Kim45
2010 Asian  ≤ 6 M 6 19 34 59 27 115 124 266
Kusztal46
2010 Caucasian  ≥ 5Y 22 – – 102 48 – – 212
Domański14
2012 Caucasian  ≤ 5Y 22 35 13 70 51 96 32 179
Gao15
2012 Asian  ≤ 6 M 4 16 25 45 16 62 44 122
Canossi18
2013 Caucasian  ≥ 6 M 18 11 5 34 11 21 2 34
Misra16
2014 Asian  ≤ 3 M 14 12 10 36 78 56 20 154
Ruhi19
2015 Caucasian  ≤ 6 M 13 17 4 34 23 20 4 47
Niknam29
2017 Iranian  ≥ 3 M 28 12 5 45 71 43 13 127
Oetting30
2019 Caucasian  > 12 M 186 176 59 421 704 957 308 1969
Oetting30
2019 African  > 12 M 30 30 11 71 147 189 70 406
Oetting30
2019 Caucasian  ≤ 12 M 157 139 49 345 733 994 318 2045
Oetting30
2019 African  ≤ 12 M 23 19 11 53 154 200 70 424
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Fig. 2A), dominant (GG/AG vs. AA, OR 0.94, 95% CI 0.73–1.22, P = 0.66; Fig. 3A) or the recessive genetic model 
(GG vs. AG/AA, OR 1.18, 95% CI 0.97–1.43, P = 0.096; Fig. 4A). The TSA for the allelic (Fig. 2B) or the dominant 
(Fig. 3B) model showed that the cumulative Z-curve (blue line) crossed neither the trial sequential monitoring 
boundaries (red inward slash), nor the conventional boundaries (black dotted line); however, it entered the futil-
ity area without reaching the required information size (G vs. A, RIS = 11,247; GG/AG vs. AA, RIS = 8,475). For 
the recessive model contrast (GG vs. AG/AA, Fig. 4B), the cumulative Z-curve crossed the futility boundary and 
reached the required information size (RIS = 4,804).
Publication bias. In overall analyses, no evidence of publication bias or small study effects was found for 
the GG/AG vs. AA model (Egger’s P-value = 0.14, Fig. 5B) and the GG vs. AG/AA model (Egger’s P-value = 0.16, 
Fig. 5C). Conversely, a statistically significant funnel plot asymmetry was detected for the G vs. A model (Egger’s 
P-value = 0.045, Fig. 5A). The trim-and-fill method for the allelic contrast model (G vs. A) imputed three missing 
studies on the left side of the funnel plot (Fig. 5D), however the adjusted effect size was still not significant (OR 
0.95; 95% CI 0.78–1.15, P = 0.57).
Subgroup and sensitivity analyses. The Q-statistic indicated the presence of between-study heteroge-
neity in the meta-analysis for the allelic (P = 0.014,  I2 = 52%) and dominant (P = 0.060,  I2 = 41%) models (Table 3), 
but not for the recessive model contrast (P = 0.33,  I2 = 11%). In order to explore possible reasons for the observed 
heterogeneity, we conducted a subgroup analysis stratified by ethnicity, as well as three sensitivity analyses by 
using the following inclusion criteria: higher study quality (NOS ≥ 7), conformation with HWE, and AR within 
one year after kidney transplantation. A significant association was detected among Asians for the allelic (G 
vs. A, OR 1.55, 95% CI 1.16–2.07, P = 0.003) or the recessive model (GG vs. GA/AA, 1.93, 95% CI 1.31–2.86, 
P = 0.001) in absence of between-study heterogeneity  (I2 = 0%), while no association with CTLA-4 rs231775 was 
found among Caucasian or African patients. Results of sensitivity analyses provided evidence of a higher risk 
of acute rejection in the first year after kidney transplantation among carriers of the rs231775GG genotype (OR 
1.37, 95% CI 1.00–1.88, P = 0.048), while no associations were detected among studies conforming to HWE or 
with a higher quality score (NOS ≥ 7) (Table 3).
Table 3.  Summary of random-effect meta-analyses for the relationship between CTLA-4 rs231775 and acute 
renal graft rejection. AR acute rejection group; HWE Hardy–Weinberg equilibrium; KT kidney transplantation; 
NAR no acute rejection group; NOS Newcastle–Ottawa scale. *Power to detect a noteworthy finding by false 











FPRP value at prior 
probability of 0.001
OR (95% CI) P-value I2 (%) P-value Power* OR = 1.5
G vs. A
Overall 13 1928/6,958 1.07 (0.88–1.30) 0.49 52 0.014 0.045
Caucasian 6 1,294/4,664 0.93 (0.77–1.12) 0.47 19 0.47
Asian 3 280/1,084 1.55 (1.16–2.07) 0.003 0 0.62 0.412 0.879
African 2 204/890 0.73 (0.46–1.15) 0.17 33 0.22
HWE 10 1666/6,296 1.02 (0.83–1.26) 0.89 51 0.030
NOS ≥ 7 9 1662/6,640 1.10 (0.89–1.36) 0.39 58 0.016
AR during the first 
year after KT 7 1,214/6,038 1.17 (0.89–1.55) 0.26 63 0.013
GG/AG vs. AA
Overall 13 964/3,479 0.94 (0.73–1.22) 0.66 41 0.060 0.14
Caucasian 6 647/2,332 0.87 (0.63–1.20) 0.40 36 0.16
Asian 3 140/542 1.38 (0.82–2.32) 0.22 0 0.71
African 2 102/445 0.47 (0.13–1.80) 0.27 62 0.10
HWE 10 833/3,148 0.87 (0.65–1.16) 0.35 38 0.10
NOS ≥ 7 9 831/3,320 0.92 (0.73–1.17) 0.50 26 0.21
AR during the first 
year after KT 8 652/3,141 1.13 (0.78–1.65) 0.51 57 0.024
GG vs. AG/AA
Overall 15 1,175/4,226 1.18 (0.97–1.43) 0.096 11 0.33 0.16
Caucasian 8 858/3,079 1.04 (0.85–1.28) 0.69 0 0.66
Asian 3 140/542 1.93 (1.31–2.86) 0.001 0 0.57 0.105 0.909
African 2 102/445 0.79 (0.45–1.38) 0.40 0 0.59
HWE 10 833/3,148 1.16 (0.89–1.51) 0.26 21 0.25
NOS ≥ 7 11 1,042/4,067 1.19 (0.96–1.48) 0.11 20 0.25
AR during the first 
year after KT 8 652/3,141 1.37 (1.00–1.88) 0.048 30 0.19 0.706 0.985
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FPRP analysis. Statistically significant findings (P < 0.05) of subgroup and sensitivity analyses were further 
investigated by using the FPRP test. At the pre-specified prior probability level of 0.001 to detect ORs of 1.50 (or 
its reciprocal 1/1.5 = 0.67), the FPRP values for the association of rs231775G or rs231775GG among Asians were 
0.879 and 0.909, respectively, while the FPRP value for the association of rs231775GG with AR in the first year 
after kidney transplantation was 0.985 (Table 3). Therefore, none of these associations was found noteworthy 
under FPRP (cutoff value < 0.2), indicating no reliable results. Similarly, analysis of significant genetic com-
parisons of previous meta-analyses on the association of CTLA-4 rs231775 and acute renal transplant rejection 
revealed FPRP values higher than 0.2, indicating lack of noteworthy results (Table 4).
Figure 2.  Forest plot (A) and TSA (B) for the association between the allelic (G vs A) genetic model of CTLA-4 
rs231775 and acute renal graft rejection. ES, effect size (i.e. odd ratio); W weight; Sig statistical significance; N 
total number of alleles; N1 number of G alleles; N2 number of A alleles. The required information size (RIS) was 
calculated based on a two side α = 5%, β = 20% (power 80%), and an “a priori” relative risk increase of 15%.
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Discussion
In the two most recent meta-analyses24,25, a higher risk of acute rejection has been reported in kidney transplant 
recipients under the GG vs. AA/AG model of CTLA-4 rs231775, but only the larger  study25 also detected a higher 
risk under the G vs. A model contrast. Given the recent publication of two novel primary studies on the risk of 
acute kidney transplant  rejection29,30, we conducted an updated meta-analysis with trial sequential analysis (TSA) 
to better estimate the impact of CTLA-4 rs231775 and to determine whether the currently available evidence was 
sufficient and conclusive. In addition, false-positive report probability (FPRP) analysis was conducted to examine 
whether the significant findings of the present or previous meta-analyses were noteworthy. To our knowledge, 
Dong and colleagues, in 2008, first applied FPRP to assess noteworthiness of meta-analytic estimates in a field 
 synopsis47. Since then, more than 40 meta-analyses of genetic association studies have been published in which 
the FPRP method was applied to examine noteworthiness of significant pooled estimates.
Figure 3.  Forest plot (A) and TSA (B) for the association between the dominant (GG + AG vs AA) genetic 
model of CTLA-4 rs231775 and acute renal graft rejection. ES effect size (i.e. odd ratio); W weight; Sig statistical 
significance; N total number of kidney transplant recipients; N1 number of patients with GG or AG genotype; 
N2 number of patients with AA genotype. The required information size (RIS) was calculated based on a two 
side α = 5%, β = 20% (power 80%), and an “a priori” relative risk reduction of 15%.
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This updated systematic review and meta-analysis, which included a total of 5,401 kidney transplant recipi-
ents, showed that CTLA-4 rs231775 is not a genetic determinant of acute rejection. Results from the traditional 
pooled analysis technique are corroborated by TSA, which provided conclusive evidence against a clinically 
relevant impact of CTLA-4 rs231775 on the risk of acute renal graft rejection under the allelic (G vs A), dominant 
(GG/AG vs AA) or the recessive model (GG vs. AG/AA). Furthermore, none of the positive findings detected in 
the subsequent subgroup and sensitivity analyses, such as association of the G allele or of the GG genotype with 
a higher risk in Asian KTRs, were found to be noteworthy by FPRP. Similarly, the application of the FPRP test 
to statistically significant results of previously published meta-analyses21–25 also revealed a lack of noteworthy 
results in the relationship between CTLA-4 rs231775 and acute renal transplant rejection. Overall, the current 
Figure 4.  Forest plot (A) and TSA (B) for the association between the recessive (GG vs AG + AA) genetic 
model of CTLA-4 rs231775 and acute renal graft rejection. ES, effect size (i.e. odd ratio); W, weight; Sig, 
statistical significance; N, total number of kidney transplant recipients; N1, number of patients with GG 
genotype; N2, number of patients with AG or AA genotype. The required information size (RIS) was calculated 
based on a two side α = 5%, β = 20% (power 80%), and an “a priori” relative risk increase of 15%.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12850  | https://doi.org/10.1038/s41598-020-69849-4
www.nature.com/scientificreports/
findings confute results of the most recent and larger meta-analysis25, which however included only 2,581 kidney 
transplant recipients.
As a key regulator of the immune response magnitude, CTLA-4 genetic variation has been placed at the 
center of attention by investigators also for a possible role in  autoimmunity48 and  cancer49. Results from tradi-
tional meta-analyses show that the GG genotype of rs231775, which is associated to lower CTLA-4 expression 
and hence to a higher T cell activation and proliferation, may confer susceptibility to development of autoim-
mune diseases, such as rheumatoid  arthritis50, Hashimoto’s  thyroiditis51 and myasthenia  gravis52. On the other 
hand, individuals with higher expression of membrane CTLA-4, due to the rs231775 A allele, may be at risk of 
developing multiple types of  cancer53. These and other evidence support the hypothesis that only an optimal 
CTLA-4 expression can ensure a state of self-tolerance54, being rs231775 G (the low-activity allele) and rs231775 
A (the high-activity allele) of CTLA-4 associated, respectively, with susceptibility to autoimmunity and cancer. 
However, the relevance of CTLA-4 rs231775 has not been consistently reported in every disease condition and 
is even less pronounced in cancer than in autoimmune  diseases54. Interestingly, a meta-analysis with TSA have 
provided convincing evidence for association of CTLA-4 rs231775 with Hashimoto’s  thyroiditis55, nevertheless 
further investigation is still needed to clarify the role of CTLA-4 rs231775 in different autoimmune disorders 
and cancer types. In this regard, future application of TSA and/or FPRP to updated meta-analyses could be of 
value for conclusive demonstration of CTLA-4 rs231775 as susceptibility risk factor for autoimmunity and cancer.
Despite strengths of the present meta-analysis, such as the use of TSA and FPRP, our findings should be 
interpreted in the light of the following limitations and considerations. First, we attempted to conduct a com-
prehensive systematic review to identify all potential relevant articles, nevertheless corresponding authors of 
some eligible publications were unable, or unavailable, to provide genotype distribution of CTLA-4 rs231775. 
Figure 5.  Funnel plots for the association between CTLA-4 rs231775 and acute renal transplant rejection. (A) 
Allelic contrast: G vs A (Egger’s P-value = 0.045). (B) Dominant contrast: GG/AG vs. AA (Egger’s P-value = 0.14). 
(C) Recessive contrast: GG vs. AG/AA (Egger’s P-value = 0.16). (D) Trim-and-fill funnel plot for the allelic 
contrast model (G vs. A, adjusted OR 0.95; 95% CI 0.78–1.15, P = 0.57).
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:12850  | https://doi.org/10.1038/s41598-020-69849-4
www.nature.com/scientificreports/
Among these, corresponding authors of two genome-wide association studies (GWASs)56,57, reporting no evi-
dence of association between CTLA-4 rs231775 and acute renal graft rejection, were unavailable to provide 
genotypes for the rs231775 SNP. Therefore, our pooled estimates must be interpreted with caution given the 
lack of inclusion of all available studies in the meta-analysis. Nevertheless, our TSA results showed that suf-
ficient cumulative evidence has been reached to conclusively exclude a clinically relevant association of the G 
allele or GG genotype of CTLA-4 rs231775 with a higher risk of acute renal graft rejection. Second, it should 
be noted that a funnel plot asymmetry, indicating potential publication bias, was indeed detected for the allelic 
model (G vs. A), which however included only 13 cohorts compared to the 15 cohorts available for the reces-
sive model (GG vs. AG/AA). In spite of this, the statistical correction for this bias, by using the trim and fill 
method, confirmed the combined risk estimate towards a null effect. Third, the majority of KTRs comprised in 
the present meta-analysis was of Caucasian ancestry (3,937 out of 5,401), therefore a clinically relevant impact 
of CTLA-4 rs231775 in other ethnic groups cannot be formally excluded. Fourth, given the large heterogene-
ity among studies in terms of immunosuppressive therapy, we were unable to evaluate the impact of rs231775 
on the risk of acute renal rejection according to a specific immunosuppressive drug. Fifth, we cannot exclude 
that CTLA-4 polymorphic variants other than rs231775 might play a role as genetic predictive factors for acute 
renal rejection. In this regard, it should be noted that a number of meta-analyses have been published on the 
association between other polymorphisms of CTLA-4 and acute renal  rejection20–22,58,59, however none of these 
studies applied TSA or FPRP for convincing evidence of an association between these additional CTLA-4 SNPs 
and acute renal allograft rejection. Finally, the lack of informative data in the identified studies precluded the 
possibility to adjust ORs for clinical confounding factors, and to investigate interaction effects of rs231775 with 
other polymorphic gene variants of CTLA-4.
In summary, findings of this systematic review and meta-analysis exclude a role of CTLA-4 rs231775 as a 
genetic risk factor for acute renal transplant rejection. This conclusion is strengthened by results of TSA, which 
provided conclusive evidence against a clinically relevant impact of CTLA-4 rs231775 on the risk of acute renal 
graft rejection in overall populations. Nevertheless, large studies comprising Asian or African kidney transplant 
recipients are still required to clarify the impact of CTLA-4 rs231775 on acute rejection risk in non-Caucasian 
populations. In addition, investigation is also warranted in kidney transplant recipients to evaluate whether 
CTLA-4 rs231775 may have an effect on the risk of acute rejection when analyzed in combination with other 
CTLA-4 gene variants.
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